Skip to main content

Table 1 Demographics data and seroprevalence of hepatitis B virus (HBV) markers and titers

From: Hepatitis B virus vaccination booster does not provide additional protection in adolescents: a cross-sectional school-based study

Age group

6 y/o

12 y/o

15 y/o

18 y/o

6-12 y/o

15-18 y/o

Item

(n = 524)

(n = 450)

(n = 1464)

(n = 4512)

(n = 974)

(n = 5976)

Gender

      

  Male, n (%)

299(57.1)

205(45.6)

740(50.5)

1657(36.7)

504(51.7)

2397(40.1)

  Female, n (%)

225(42.9)

245(54.4)

724(49.5)

2855(63.3)

470(48.3)

3579(59.9)

Age (Mean ± SD, yr)

6.5 ± 0.3

12.5 ± 0.3

15.5 ± 0.5

18.7 ± 0.7

9.3 ± 3.0

17.9 ± 1.5

Anti-HBs (+), n

332

142

574

2033

474

2607

(%, 95% CI)

(63.4, 59.3-67.5)

(31.6, 27.3-35.9)

(39.2, 36.7-41.7)

(45.1, 43.6-46.6)

(48.7, 45.6-51.8)

(43.6, 42.3-44.9)

Anti-HBs (−), n

192

308

890

2479

500

3369

(%, 95% CI)

(36.6, 32.5-40.7)

(68.4, 64.1-72.7)

(60.8, 58.3-63.3)

(54.9, 53.4-56.4)

(51.3, 48.2-54.4)

(56.4, 55.1-57.7)

  P-value

<0.001*

0.003*

Anti-HBs median titer

21.2

NA

3.9

4.8

21.2

4.6

  P-value

<0.001*

<0.001*

HBsAg (+), n

1

7

16

56

8

72

(%, 95% CI)

(0.2, 0.0-0.6)

(1.6, 0.4-2.8)

(1.1, 0.6-1.6)

(1.2, 0.9-1.5)

(0.8, 0.2-1.4)

(1.2, 0.9-1.5)

HBsAg (−), n

523

443

1448

4456

966

5904

(%, 95% CI)

(99.8, 99.4-100.0)

(98.4, 97.2-99.6)

(98.9, 98.4-99.4)

(98.8, 98.5-99.1)

(99.2, 98.6-99.8)

(98.8, 98.5-99.1)

  P-value

0.154

0.336

  1. Note: Anti-HBs, antibody to HBV surface antigen; HBsAg, HBV surface antigen; y/o, year old; NA, not available; 95% CI, 95% confidence interval; Data are presented as or n and percentage.
  2. *p-value < 0.05 was considered statistically significant after test.